1. Home
  2. Stocks
  3. Astrazen Share Price

AstraZeneca Pharma India Share Price

Pharmaceuticals Mid Cap

₹7,490.60 +139.15 (1.89%)

05 Nov, 2024 17:15

SIP TrendupStart SIP in ASTRAZEN

Start SIP
Performance Financial Technical Events FnO Shareholding Pattern More FAQ’s

Performance

  • Low
  • ₹7,232
  • High
  • ₹7,661
  • 52 Week Low
  • ₹4,510
  • 52 Week High
  • ₹8,139
  • Open Price₹7,325
  • Previous Close₹7,351
  • Volume21,963

Investment Returns

  • Over 1 Month + 0.72%
  • Over 3 Month + 6.4%
  • Over 6 Month + 37.82%
  • Over 1 Year + 60.55%
SIP Lightning

Smart Investing Starts Here Start SIP with AstraZeneca Pharma India for Steady Growth!

AstraZeneca Pharma India Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 195.4
  • PEG Ratio
  • -7
  • Market Cap Cr
  • 18,727
  • P/B Ratio
  • 26.3
  • Average True Range
  • 285.21
  • EPS
  • 59.6
  • Dividend Yield
  • 0.3
  • MACD Signal
  • 36.06
  • RSI
  • 49.42
  • MFI
  • 40.5

AstraZeneca Pharma India Financial

IndicatorJun 24Mar 24Dec 23Sep 23Jun 23
Net Sales/Income from operations387.52383.20305.79311.07295.47
Total Income From Operations387.52383.20305.79311.07295.47
P/L Before Interest, Excpt. Items & Tax42.5254.2921.0157.4671.55
P/L Before Exceptional Items & Tax42.4154.3520.4056.9671.40
P/L After Tax from Ordinary Activities-11.7939.4815.8052.3753.86
Net Profit/Loss For the Period-11.7939.4815.8052.3753.86
IndicatorMar 24Mar 23
Revenue From Operations [Gross]1,295.531,002.97
Revenue From Operations [Net]1,295.531,002.97
Total Operating Revenues1,295.531,002.97
Total Revenue1,330.331,029.07
Total Expenses1,127.22854.74
Profit/Loss Before Tax219.54134.10
Profit/Loss For The Period161.5199.29
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity27.8758.29
Net Cash Used In Investing Activity21.7418.11
Net Cash Used in Finance Activity-44.38-24.48
Net Inc/Dec In Cash And Equivalent5.2351.92
Cash And Equivalent End Of Year505.57500.34
IndicatorMar 24Mar 23
Total Share Capital5.005.00
Total Non-Current Liabilities8.9912.25
Total Current Liabilities357.12383.93
Total Capital And Liabilities1,078.03984.87
Total Non-Current Assets145.32149.40
Total Current Assets932.71835.47
Total Assets1,078.03984.87
Indicator20242023
EBIT Margin (%)15.7717.44
Return On Capital Employed (%)28.3429.11
Return On Equity (%)22.6816.86
Long Term Debt To Equity (%)0.000.00
Book Value/Share (INR)284.77235.48
Indicator20242023
EBIT Margin (%)15.7717.44
Return On Capital Employed (%)28.3429.11
Return On Equity (%)22.6816.86
Long Term Debt To Equity (%)0.000.00
Book Value/Share (INR)284.77235.48

AstraZeneca Pharma India Technicals

EMA & SMA

Current Price
₹7,490.60
+ 139.15 (1.89%)
pointer
  • stock-down_img
  • Bullish Moving Average 15
  • stock-up_img
  • Bearish Moving Average 1
  • 20 Day
  • ₹7,395.89
  • 50 Day
  • ₹7,238.38
  • 100 Day
  • ₹6,914.53
  • 200 Day
  • ₹6,352.21

Resistance and Support

7372.33 Pivot Speed
  • R3 7,863.57
  • R2 7,706.78
  • R1 7,529.12
  • S1 7,194.67
  • S2 7,037.88
  • S3 6,860.22

Is AstraZeneca Pharma India Worth Buying?

BUY SELL HOLD

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

AstraZeneca Pharma India Ltd. is a global, science-led pharmaceutical company dedicated to transforming healthcare through innovative medicines in oncology, biopharmaceuticals, and rare diseases. it focuses on improving patient outcomes and advancing healthcare worldwide. Astrazeneca Pharma India has an operating revenue of Rs. 1,387.58 Cr. on a trailing 12-month basis. An annual revenue growth of 29% is outstanding, Pre-tax margin of 17% is great, ROE of 22% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 6% and 21% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around -2% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 52 which is a POOR score indicating inconsistency in earnings, a RS Rating of 66 which is FAIR indicating the recent price performance, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 35 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

AstraZeneca Pharma India Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-13 Quarterly Results
2024-08-08 Quarterly Results
2024-05-27 Audited Results & Dividend
2024-02-08 Quarterly Results
2023-11-09 Quarterly Results
Date Purpose Remarks
2024-07-05 FINAL Rs.24.00 per share(1200%)Dividend
2023-07-14 FINAL Rs.16.00 per share(800%)Dividend
2022-07-08 FINAL Rs.8.00 per share(400%)Final Dividend
2021-08-20 INTERIM Rs.2.00 per share(100%)Interim Dividend

AstraZeneca Pharma India F&O

AstraZeneca Pharma India Shareholding Pattern

75%
5.05%
0%
2.9%
0%
14.78%
2.27%
  • NSE Symbol
  • ASTRAZEN
  • BSE Symbol
  • 506820
  • ISIN
  • INE203A01020

AstraZeneca Pharma India FAQs

AstraZeneca Pharma India share price is ₹7,490 As on 05 November, 2024 | 17:01

The Market Cap of AstraZeneca Pharma India is ₹18726.5 Cr As on 05 November, 2024 | 17:01

The P/E ratio of AstraZeneca Pharma India is 195.4 As on 05 November, 2024 | 17:01

The PB ratio of AstraZeneca Pharma India is 26.3 As on 05 November, 2024 | 17:01

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

The Vigilance Awareness Week for the year 2024 (VAW 2024) would be observed from October 28, 2024 to November 03, 2024
“सत्यनिष्ठा की संस्कृनि सेराष्र की समद्ृधि” “Culture of Integrity for Nation's Prosperity”
e-pledge link (https://pledge.cvc.nic.in/)

5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

*Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

Contact Us

Attention Investors

  • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
  • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Email: support@5paisa.com

Support Desk Helpline: 8976689766

©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.